Phase 1/2 Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)

  • Hildebrandt, Gerhard (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date5/16/19 → 3/14/22